methylcobalamin + saline solution
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Amyotrophic Lateral Sclerosis
Conditions
Amyotrophic Lateral Sclerosis
Trial Timeline
Nov 1, 2017 → Feb 18, 2025
NCT ID
NCT03548311About methylcobalamin + saline solution
methylcobalamin + saline solution is a phase 3 stage product being developed by Eisai for Amyotrophic Lateral Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03548311. Target conditions include Amyotrophic Lateral Sclerosis.
What happened to similar drugs?
2 of 17 similar drugs in Amyotrophic Lateral Sclerosis were approved
Approved (2) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03548311 | Phase 3 | Completed |
Competing Products
20 competing products in Amyotrophic Lateral Sclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo | Alector | Phase 2 | 17 |
| 89Zr-DFO-AP-101 | Eli Lilly | Phase 1 | 33 |
| Reldesemtiv + Placebo | Astellas Pharma | Phase 2 | 35 |
| Perampanel + Placebo Oral Tablet | Eisai | Pre-clinical | 18 |
| E0302 (mecobalamin) | Eisai | Phase 2/3 | 38 |
| E0302 (mecobalamin) + E0302 (mecobalamin) + Placebo | Eisai | Phase 2/3 | 38 |
| ONO-2506PO | Ono Pharmaceutical | Phase 2 | 35 |
| ONO-2506PO + ONO-2506PO | Ono Pharmaceutical | Phase 2 | 35 |
| ZYIL1 capsules 25 mg and 50 mg Placebo + ZYIL1 capsules 50 mg and 25 mg Placebo + ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg + Matching placebo 25 mg and Matching placebo 50 mg | Zydus Lifesciences | Phase 2 | 35 |
| LY4256984 + Placebo | Eli Lilly | Phase 1 | 36 |
| TCH346 | Novartis | Phase 2 | 35 |
| VHB937 | Novartis | Phase 2 | 39 |
| TCH346 | Novartis | Phase 2 | 35 |
| TCH346 | Novartis | Phase 2 | 35 |
| BLZ945 | Novartis | Phase 2 | 27 |
| TRO19622 | Roche | Phase 2/3 | 38 |
| Olesoxime + Placebo Comparator + Riluzole | Roche | Phase 3 | 40 |
| Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part) | Pfizer | Phase 1/2 | 28 |
| Celecoxib + Creatine + Minocycline | Pfizer | Phase 2 | 35 |
| DNL747 + Placebo | Sanofi | Phase 1 | 21 |